Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 319

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 319
---
 the closing of the IPO, Iris began paying a then-affiliate of the Sponsor, Tribe Capital, a total of $10,000 per month for office space, secretarial and administrative services provided to members of Iris’s management team. On March 11, 2024, the Company entered into an administrative support agreement (the “Agreement”) with Arrow Capital Management LLC (“Arrow”). Pursuant to the Agreement, Arrow will provide certain office space, utilities and secretarial and administrative support (the “Services”) to the Company. In exchange for the Services, the Company will pay to Arrow $10,000 per month, beginning January 1, 2024, and continuing until the earlier of the consummation by the Company of an initial business combination or the Company’s liquidation. On August 30, 2024, the Company amended the Agreement with Arrow. In exchange for the Services mentioned above, the Company will pay to Arrow $30,000 per month, beginning September 1, 2024, and continuing until the earlier of the consummation by the Company of an initial business combination or the Company’s liquidation. Iris considers its current office space adequate for its current operations. Upon completion of the Business Combination or its liquidation, it will cease paying these monthly fees. Employees Iris currently has three executive officers, Sumit Mehta, Lisha Parmar and Omkar Halady. Our executive officers are not obligated to devote any specific number of hours to our matters but they intend to devote as much of their time as they deem necessary to Iris’s affairs until Iris has completed the Business Combination. The amount of time they will devote in any time period will vary based on the stage of the Business Combination process Iris is in. Iris does not intend to have any full time employees prior to the completion of the Business Combination. Directors and Executive Officers The below lists Iris’s officers and directors as of January 2, 2025. Concurrently with the consummation of the Business Combination, Iris’s officers and directors will resign from their respective positions at Iris and we expect that Mr. Chris Kim will be appointed as the President and Chief Executive Officer, Mr. Scott Dam, will be appointed as Chief Financial Officer, Mr. Byong C Yoo will be appointed Chief Science Officer, Mr. Sang-jin Daniel Lee will be appointed Head of Research and Development, and Mr. Beom K. Choi will be appointed as Chief Technology Officer.

| Name               | ​ | ​ | Age | ​ | ​ |